Table 2.

Total number of tests received during 5 years of follow-up for prostate cancer patients managed with observation for a minimum of 5 years, based on diagnosis period.

	2004–2014		Diagnosis Period
	2004–2014		2004–2009		2010–2014
	n	%	n	%	n	%	p
Number of patients	4,258		1,072		3,186
Number of PSA tests
Median (IQR)	9 (6–12)		9 (5–12)		9 (6–12)		0.002
0	135	3.2	48	4.5	87	2.7
1–4	572	13	164	15	408	13
5–9	1507	35	387	36	1120	35
10–19	1923	45	437	41	1486	47
≥20	121	2.8	36	3.4	85	2.7
Number of prostate biopsies
Median (IQR)	1 (1–2)		1 (1–2)		1 (1–2)		<0.001
1 (no repeat biopsy)	2577	61	792	74	1785	56
2	975	23	181	17	794	25
3	476	11	67	6.3	409	13
≥4	230	5.4	32	3.0	198	6.2
Prostate MRI
Median (IQR)	0 (0–1)		0 (0–1)		0 (0–1)		<0.001
0	3,425	80	1,007	94	2,418	76
1	506	12	54	5.0	452	14
2	187	4.4	^†	^†	>176	>5.5
≥3	140	3.3	^†	^†	>129	>4.0
Protocol Adherence
≥10 PSA and ≥2 biopsies	1007	24	170	16	837	26	<0.001
PRIAS 8 (≥14 PSA and ≥2 biopsies)	377	8.9	60	5.6	317	9.9	<0.001
Johns Hopkins14 (≥10 PSA tests and ≥4 biopsies)	159	3.7	21	2.0	138	4.3	<0.001

Abbreviations: PSA=prostate specific antigen; IQR=interquartile range; PRIAS=Prostate Cancer Research International Active Surveillance Study;

^†

Value suppressed due to cell size <11; CI=confidence interval

Percentages may not add up to 100 due to rounding.